Last reviewed · How we verify
new thermo stable formulation of epoprostenol sodium
new thermo stable formulation of epoprostenol sodium is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved.
At a glance
| Generic name | new thermo stable formulation of epoprostenol sodium |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- new thermo stable formulation of epoprostenol sodium CI brief — competitive landscape report
- new thermo stable formulation of epoprostenol sodium updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about new thermo stable formulation of epoprostenol sodium
What is new thermo stable formulation of epoprostenol sodium?
new thermo stable formulation of epoprostenol sodium is a Small molecule drug developed by GlaxoSmithKline.
Who makes new thermo stable formulation of epoprostenol sodium?
new thermo stable formulation of epoprostenol sodium is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is new thermo stable formulation of epoprostenol sodium in?
new thermo stable formulation of epoprostenol sodium is FDA-approved (marketed).